verified SJR 1,243 · Q1 • database Scopus / SJR & Web of Science indexed

Hong Kong · AME Publishing Company

workspace_premium Q1 — Oncology lock Subscription

Translational Lung Cancer Research

Translational Lung Cancer Research is a journal indexed in SJR in Oncology with an H index of 70. It has an SJR impact factor of 1,243 and it has a best quartile of Q1. It has an SJR impact factor of 1,243.

ISSN: 2218-6751

Publisher: AME Publishing Company

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,243 Q1

H-index 70

Acceptance rate pie_chart

31%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,243

H-index

Docs (year)

324

Docs 3y

835

Total refs

12307

Cites 3y

2768

Citable 3y

725

Cites/Doc 2y

2.72

Ref/Doc

37.98

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer

Type 2 diabetes mellitus does not increase the risk of lung cancer among never-smokers: a nationwide cohort study

Differentiation of non-small cell lung cancer and histoplasmosis pulmonary nodules: insights from radiomics model performance compared with clinician observers

Cystic brain metastases and RET fusion in lung cancer

Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer

CT-based radiomics signature for the stratification of N2 disease risk in clinical stage I lung adenocarcinoma

Comparison of robotic-assisted lobectomy with video-assisted thoracic surgery for stage IIB-IIIA non-small cell lung cancer

Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next

Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort

Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy

Circ-ZKSCAN1 regulates FAM83A expression and inactivates MAPK signaling by targeting miR-330-5p to promote non-small cell lung cancer progression

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?

SHOW MORE ARTICLES

CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?

Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach

Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19

Can the assessment of lymphocyte exhaustion serve as a prognostic predictor after lung cancer surgery?

Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach?

Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor na?Øve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

Awareness: potential toxicities of carbon nanotubes

Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases

Application of the CARE guideline as reporting standard in the Translational Lung Cancer Research

Anti-PDL1 effect in squamous non-small cell lung cancer

Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer

FAQs

Translational Lung Cancer Research has an SJR of 1,243 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Translational Lung Cancer Research is 31%.

Translational Lung Cancer Research

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Translational Lung Cancer Research?

What is the APC / publication cost?

What is the acceptance rate?